Cite

HARVARD Citation

    Abdulrehman, J. et al. (2021). Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals. Research and practice in thrombosis and haemostasis. 5 (5), p. n/a. [Online]. 
  
Back to record